AXSM Q2 2022 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M

Gross Profit

$8M88.9% margin

Operating Income

-$39M-444.2% margin

Net Income

-$41M-469.8% margin

EPS (Diluted)

$-1.06

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$181M

Total Liabilities

$165M

Stockholders' Equity

$15M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$0	—
Gross Profit	$8M	$0	—
Operating Income	-$39M	-$31M	-27.0%
Net Income	-$41M	-$32M	-28.4%